About Samsung BioLogics
Samsung BioLogics is a publicly listed company based in Incheon (South Korea) founded in 2011. Contract development and manufacturing for biologics are provided. The company has 5,010 employees. Samsung BioLogics has completed 2 acquisitions, including Human Genome Sciences and Samsung Bioepis. Its website samsungbiologics.com draws about 52 thousand monthly visits. Its focus areas include Biopharma Outsourcing, Diversified and Biologics.
Company details
Samsung BioLogics was established in 2011 in Incheon, South Korea. Services as a contract development and manufacturing organization (CDMO) in the biologics sector are offered by the company. Development and production of biologic pharmaceuticals are handled, with operations based in South Korea. Global pharmaceutical clients are supported through these manufacturing capabilities, focusing on biopharmaceutical processes and quality standards.
- Headquarters Incheon, South Korea
- Employees 5,010
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website samsungbiologics.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name Samsung Biologics Co., Ltd.
- Annual Revenue$3.16 B (USD)30.31as on Dec 31, 2025
- Net Profit$1.23 B (USD)64.71as on Dec 31, 2025
- EBITDA$1.87 B (USD)40.74as on Dec 31, 2025
- Employee Count5,010
- Investments & AcquisitionsHuman Genome Sciences
& 1 more
Apps and channels of Samsung BioLogics
its YouTube channel Samsung Biologics has 7.9K subscribers and 30 videos.
Videos from Samsung BioLogics
The most watched videos on Samsung BioLogics's YouTube channel, Samsung Biologics (7.9K subscribers). Click a video to play it here.
More on Samsung Biologics.
People of Samsung BioLogics
134 people are tracked at Samsung BioLogics (48 in leadership, 86 in team); the tracked headcount is 5,010.
| Name | Role | Group |
|---|---|---|
Mary Lee Schiesz | Senior Director, CDMO Business Development, North America & Europe | Leadership |
Claire Kim | Head Of Marketing Communications | Leadership |
Hyungwoo Moon | VP, Head of Legal Compliance | Leadership |
Daniel Kim | APAC Sales Head | Leadership |
John Gagliardi | Sales Director, Key Account Management | Leadership |
Kun Lo | Executive Vice President | Leadership |
Dongjoong Kim | Executive Vice President | Leadership |
James Choi | VP and Chief Information Officer | Leadership |
John Rim | President & CEO | Leadership |
Javier Camposano | Sales & Operations VP | Leadership |
Thomas Chu | Lead CSV And Automation Validation Quality (director) | Leadership |
Yunjin Hong | Head Of Quality Assurance | Leadership |
Jeffrey Mason | Vice President Sales, Samsung Biologics America | Leadership |
Jevon Hsiao | Senior Director & Group Leader, Manufacturing Validation & Drug Substance Manufacturing Support | Leadership |
Wonjoon Lee | Executive Vice President and Head of Finance | Leadership |
Hyeongnam Jeong | Executive Vice President and Head of the Bio R&D Center | Leadership |
Joonho Hwang | Vice President and Executive in Charge of Business Strategy | Leadership |
Hosung Min | Executive Vice President and Head of CDO Development Center | Leadership |
Heekyun Lim | VP, Head of Business Consulting | Leadership |
Pierre Catignol | EVP & Head of Operation Center | Leadership |
114 more people are available in the full profile.
Complete people profiles for Samsung BioLogics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Samsung BioLogics
Samsung BioLogics is a publicly listed company on the KRX with ticker symbol 207940 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Nov 2016
- Listed onKRX: 207940
- Listed entitySAMSUNG BIOLOGICS Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7207940008
- Share price1,182,000.00 KRW (-1.99% on the day) · 2026-10-14
- Market capitalisation58,019,432,395,935.00 KRW
- Price to earnings27.7
- EPS (diluted, trailing year)42,610.69 KRW
- Volume (last session)52,364
Financials of Samsung BioLogics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4,560.00B KRW | 1,780.00B KRW | 2,700.00B KRW |
| 2024 | 3,500.00B KRW | 1,080.00B KRW | 1,920.00B KRW |
| 2023 | 3,690.00B KRW | 857.69B KRW | 1,600.00B KRW |
| 2022 | 3,000.00B KRW | 798.06B KRW | 1,290.00B KRW |
| 2021 | 1,570.00B KRW | 393.59B KRW | 699.10B KRW |
Detailed financial statements for Samsung BioLogics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Samsung BioLogics
Samsung BioLogics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Human Genome Sciences and Samsung Bioepis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene-based drugs for lupus, hepatitis C, inhalation anthrax and cancer. | hgsi.com | Rockville, United States | 1992 | Dec 2025 | •••• | |
Developer of biosimilar drugs for the treatment of multiple diseases | samsungbioepis.com | Incheon, South Korea | 2012 | Jan 2022 | $2.3B |
Complete acquisition details for Samsung BioLogics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Samsung BioLogics
4 dated milestones of Samsung BioLogics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Samsung BioLogics is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Samsung Bioepis.
- Acquisition Acquires Human Genome Sciences.
Web traffic of Samsung BioLogics
The website of Samsung BioLogics (samsungbiologics.com) receives about 52K visits a month and ranks #483,833 among all websites worldwide, #470 in Biotechnology and Pharmaceuticals.
- Monthly visits52K
▲ 13.4% vs previous month
- Unique visitors24.8K
per month
- Global rank#483,833
among all websites
- Category rank#470
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit5.1
- Average visit1 min 42 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Samsung BioLogics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| samsungbioepis.com | 100% | 16.1K | #1,543,552 | View details | |
| biotoxtech.com | 90% | 11.1K | #689,683 | View details | |
| celltrion.com | 90% | 179.3K | #287,455 | View details | |
lifescienceleader.com | lifescienceleader.com | 89% | #2,544,825 | – | |
kobia.kr | kobia.kr | 62% | #1,570,244 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Samsung BioLogics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Samsung Biologics
Complete news archive for Samsung BioLogics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Samsung BioLogics
Samsung BioLogics was founded in 2011.
Samsung BioLogics is headquartered in Incheon, South Korea.
Samsung BioLogics has 5,010 employees.
Annual revenue of Samsung BioLogics is $3.16B as on Dec 31, 2025.
Samsung BioLogics was established in 2011 in Incheon, South Korea. Services as a contract development and manufacturing organization (CDMO) in the biologics sector are offered by the company. Development and production of biologic pharmaceuticals are handled, with operations based in South Korea. Global pharmaceutical clients are supported through these manufacturing capabilities, focusing on biopharmaceutical processes and quality standards.
Yes, Samsung BioLogics is publicly traded on KRX under the ticker symbol 207940.
Samsung BioLogics has made 2 acquisitions, including Human Genome Sciences, and Samsung Bioepis.